中华医学杂志
中華醫學雜誌
중화의학잡지
National Medical Journal of China
2013年
26期
2052-2055
,共4页
聂晓敏%赵迎新%史冬梅%刘宇杨%周志明%苏利霄%周玉杰
聶曉敏%趙迎新%史鼕梅%劉宇楊%週誌明%囌利霄%週玉傑
섭효민%조영신%사동매%류우양%주지명%소리소%주옥걸
冠状动脉疾病%糖尿病%PCI术%内皮,血管%大蒜素
冠狀動脈疾病%糖尿病%PCI術%內皮,血管%大蒜素
관상동맥질병%당뇨병%PCI술%내피,혈관%대산소
Coronary artery disease%Diabetes mellitus%Percutaneous coronary intervention%Endothelium%vascular%Allitridi
目的 观察大蒜素胶囊对冠心病合并糖尿病患者经皮冠状动脉介入治疗(PCI)术后预后及内皮功能的影响.方法 连续入选拟行PCI术的冠心病合并糖尿病住院患者,数字表法随机分为对照组(n=60例)和大蒜素组(n=60例).对照组给予常规治疗,药物组在常规治疗基础上加用大蒜素胶囊口服,每次40mg(2粒),3次/d,共3个月.分别于PCI术后即刻和3个月抽取外周静脉血,检测患者血清一氧化氮(NO)和细胞间黏附分子l(ICAM-1)水平；采用高分辨率彩色多普勒超声仪测定患者肱动脉内皮依赖性血流介导的血管舒张功能(FMD).所有患者PCI术后随访1年.结果 对照组和大蒜素组患者的临床基线资料差异无统计学意义(P＞0.05),基础FMD水平和血清NO、ICAM-1水平差异无统计学意义(P＞0.05).PCI术后3个月,两组患者的临床资料情况差异无统计学意义,与对照组相比,大蒜素组患者FMD显著改善[(8.2±2.4)％比(6.4±2.3)％,P=0.013),血清NO水平升高[(147±32) μmol/L比(112±24) μmol/L,P=0.009],ICAM-1水平下降[(182±21)μmol/L比(232±29)μmol/L,P=0.021].PCI术后1年,大蒜素组主要不良心血管事件发生率为10.5％,显著低于对照组(17.2％,P=0.022).结论 冠心病合并糖尿病患者PCI术后口服大蒜素胶囊可改善临床预后,其机制可能与大蒜素改善血管内皮功能和血管炎症状态相关.
目的 觀察大蒜素膠囊對冠心病閤併糖尿病患者經皮冠狀動脈介入治療(PCI)術後預後及內皮功能的影響.方法 連續入選擬行PCI術的冠心病閤併糖尿病住院患者,數字錶法隨機分為對照組(n=60例)和大蒜素組(n=60例).對照組給予常規治療,藥物組在常規治療基礎上加用大蒜素膠囊口服,每次40mg(2粒),3次/d,共3箇月.分彆于PCI術後即刻和3箇月抽取外週靜脈血,檢測患者血清一氧化氮(NO)和細胞間黏附分子l(ICAM-1)水平；採用高分辨率綵色多普勒超聲儀測定患者肱動脈內皮依賴性血流介導的血管舒張功能(FMD).所有患者PCI術後隨訪1年.結果 對照組和大蒜素組患者的臨床基線資料差異無統計學意義(P＞0.05),基礎FMD水平和血清NO、ICAM-1水平差異無統計學意義(P＞0.05).PCI術後3箇月,兩組患者的臨床資料情況差異無統計學意義,與對照組相比,大蒜素組患者FMD顯著改善[(8.2±2.4)％比(6.4±2.3)％,P=0.013),血清NO水平升高[(147±32) μmol/L比(112±24) μmol/L,P=0.009],ICAM-1水平下降[(182±21)μmol/L比(232±29)μmol/L,P=0.021].PCI術後1年,大蒜素組主要不良心血管事件髮生率為10.5％,顯著低于對照組(17.2％,P=0.022).結論 冠心病閤併糖尿病患者PCI術後口服大蒜素膠囊可改善臨床預後,其機製可能與大蒜素改善血管內皮功能和血管炎癥狀態相關.
목적 관찰대산소효낭대관심병합병당뇨병환자경피관상동맥개입치료(PCI)술후예후급내피공능적영향.방법 련속입선의행PCI술적관심병합병당뇨병주원환자,수자표법수궤분위대조조(n=60례)화대산소조(n=60례).대조조급여상규치료,약물조재상규치료기출상가용대산소효낭구복,매차40mg(2립),3차/d,공3개월.분별우PCI술후즉각화3개월추취외주정맥혈,검측환자혈청일양화담(NO)화세포간점부분자l(ICAM-1)수평；채용고분변솔채색다보륵초성의측정환자굉동맥내피의뢰성혈류개도적혈관서장공능(FMD).소유환자PCI술후수방1년.결과 대조조화대산소조환자적림상기선자료차이무통계학의의(P＞0.05),기출FMD수평화혈청NO、ICAM-1수평차이무통계학의의(P＞0.05).PCI술후3개월,량조환자적림상자료정황차이무통계학의의,여대조조상비,대산소조환자FMD현저개선[(8.2±2.4)％비(6.4±2.3)％,P=0.013),혈청NO수평승고[(147±32) μmol/L비(112±24) μmol/L,P=0.009],ICAM-1수평하강[(182±21)μmol/L비(232±29)μmol/L,P=0.021].PCI술후1년,대산소조주요불양심혈관사건발생솔위10.5％,현저저우대조조(17.2％,P=0.022).결론 관심병합병당뇨병환자PCI술후구복대산소효낭가개선림상예후,기궤제가능여대산소개선혈관내피공능화혈관염증상태상관.
Objective To explore the effects of allitridi capsules on endothelial function and clinical prognosis after percutaneous coronary intervention (PCI) in coronary artery disease (CAD) patients with diabetes mellitus(DM).Methods A total of 120 CAD patients with DM undergoing PCI were randomly assigned to receive conventional(control,n =60) and additional allitridi treatment(120 mg/day,n =60) for 3 months.Serum nitric oxide(NO) and intercellular adhesion molecule 1 (ICAM-1) levels were determined by enzyme-linked immunosorbent assay(ELISA) immediately and at 3 months post-PCI.Endothelial function was assessed by endothelium dependent flow-mediated dilation(FMD).Duration of follow-up was 1 year after PCI.Results The clinical characteristics,serum NO and ICAM-1 levels and FMD at baseline were not different between two groups.At Month 3 post-PCI,serum NO level was markedly higher ((147 ± 32) vs (112 ± 24) μmoL/L,P =0.009) and serum ICAM-1 level was significantly lower ((182 ± 21) vs (232 ±29) μmol/L,P =0.021)in the allitridi group than in the control group.Furthermore,treatment of allitridi resulted in a significant improvement of FMD (8.2％ ± 2.4％ vs 6.4％ ± 2.3％,P =0.013).At Year 1post-PCI,the incidence of major adverse cardiovascular event(MACE) was lower in the allitridi group than that in the control group (10.5％ vs 17.2％,P =0.022).Conclusions Allitridi capsules significantly improve the clinical prognosis after PCI in CAD patients with DM.Its mechanism may lies in improved endothelial function and vascular inflammatory state.
